Cipla’s partner Akorn Inc (Akorn), a niche speciality pharmaceutical company, has announced the launch of oral Vancocin in the US.
This comes shortly after Cipla started generic Lexapro supplies to Teva. Analysts estimate Vancocin to add Rs 0.25 share on recurring basis to Cipla’s EPS, while Lexapro supplies would add Rs 1.5 share on NPV basis during the 180 day exclusivity period.
While each of these products may not be significant as standalones, they add up to improve traction in Cipla’s exports, which have slowed recently.
Moreover, pick-up in Seroflo in Russia and South Africa will further boost exports. Maintain buy.
Review By ICICI Securities
No comments:
Post a Comment